Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy

被引：0

作者：

Gold, Linda Stein ^{[1
]}

Kircik, Leon ^{[2
,3
,4
]}

Sugarman, Jeffrey ^{[5
]}

Lin, Tina ^{[6
]}

Pillai, Radhakrishnan ^{[7
]}

Varughese, Johnson ^{[7
]}

机构：

[1] Henry Ford Hosp, Detroit, MI 48202 USA

[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[3] Phys Skin Care PLLC, Louisville, KY USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Ortho Dermatol, Bridgewater, NJ USA

[7] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9859

引用

页码：AB69 / AB69

页数：1

共 50 条

[21] Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study
Lebwohl, M. G.
Stein Gold, L.
Papp, K.
Han, G.
Pariser, D. M.
Lin, T.
Harris, S.
Jacobson, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1152 - 1160
[22] THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
Lakzadeh, P.
Lozano-Ortega, G.
Gaudet, V
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2019, 22 : S363 - S364
[23] A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis
Radonjic, Aleksandar
Evans, Emily L.
DERMATOLOGIC THERAPY, 2019, 32 (04)
[24] Real-world treatment outcomes with halobetasol propionate 0.01%/ tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
Vender, Ronald
Turchin, Irina
Lansang, Perla
Prajapati, Vimal H.
Legault, Mark
Barakat, Maxime
Yeung, Jensen
JAAD INTERNATIONAL, 2022, 8 : 60 - 63
[25] Halobetasol and tazarotene: Further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis in a Hispanic population
Yamauchi, Paul S.
Bhatia, Neal D.
Green, Lawrence J.
Lin, Tina
Martin, Gina
Harris, Susan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB218 - AB218
[26] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
Desai, Seemal R.
Alexis, Andrew F.
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
[27] Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
Sugarman, Jeffrey L.
Weiss, Jonathan
Tanghetti, Emil A.
Bagel, Jerry
Yamauchi, Paul S.
Gold, Linda Stein
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
Israel, Robert
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 855 - 861
[28] Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
Desai, Seemal R.
Glick, Brad
Del Rosso, James Q.
Harris, Susan
Jacobson, Abby
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (03) : 252 - 258
[29] Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne
Del Rosso, James
Gold, Linda Stein
Tyring, Stephen
Zeichner, Joshua
Callender, Valerie
Draelos, Zoe
Werschler, William
Cook-Bolden, Fran
Guenin, Eric
JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (10) : 1061 - 1069
[30] Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis
Lebwohl, Mark G.
Del Rosso, James Q.
Alonso-Llamazares, Javier
Lattouf, Mark
Jacobson, Abby
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB130 - AB130

← 1 2 3 4 5 →